Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP18dm0107094, JP18dm0207007)
Japan Society for the Promotion of Science (26860957, 26118518, 26119531,24791251,17H02173)
Received: 24 April 2018
Accepted: 1 June 2018
First Online: 14 June 2018
Ethics approval and consent to participate
: This study was approved by the Radiation Drug Safety Committee and the Institutional Review Board of National Institute of Radiological Sciences of Japan. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants.
: YK, MH, and TS are involved in a joint research and clinical trial sponsored by Taisho Pharmaceutical Co., Ltd. MH and TS hold a patent for [<sup>11</sup>C] TASP457 and related chemicals as H<sub>3</sub> ligands (Japan patent JP2014-47209A).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.